Cardiovascular Medicine
Showing 51-100 of 126 Results
-
Kiran Khush, MD
Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly InterestsDr. Khush's clinical research interests include the evaluation of donors and recipients for heart transplantation; mechanisms of adverse outcomes after heart transplantation, including cardiac allograft vasculopathy and antibody-mediated rejection; and development of non-invasive diagnostic approaches for post-transplant monitoring.
-
Gloria S. Kim
Clinical Associate Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsMedical education
Health services delivery
Management of chronic disease
Patient and physician satisfaction -
Juyong Brian Kim
Assistant Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly InterestsThe lifetime risk of developing cardiovascular disease (CVD) is determined by the genetic makeup and exposure to modifiable risk factors. The Cardiovascular Link to Environmental ActioN (CLEAN) Lab is interested in understanding how various environmental pollutants (eg. tobacco, e-cigarettes, air pollution and wildfire) interact with genes to affect the transcriptome, epigenome, and eventually disease phenotype of CVD. The current focus is to investigate how different toxic exposures can adversely remodel the vascular wall leading to increased cardiac events. We intersect human genomic discoveries with animal models of disease, in-vitro and in-vivo systems of exposure, single-cell sequencing technologies to solve these questions. Additionally, we collaborate with various members of the Stanford community to develop biomarkers that will aid with detection and prognosis of CVD. We are passionate about the need to reduce the environmental effects on health through strong advocacy and outreach.
(http://kimlab.stanford.edu) -
Joshua W. Knowles
Associate Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly InterestsGenetic basis of coronary disease
Genetic basis of insulin resistance
Familial Hypercholesterolemia (FH) -
Byron Lee
Professor of Medicine (Cardiovascular)
BioDr. Byron Lee is Professor of Medicine in the Stanford Division of Cardiovascular Medicine and Cardiac Electrophysiology Section. He has published over 150 peer reviewed articles and 10 book chapters. He has written two books to help students navigate the medical school admission process: Insider's Premed Guidebook and Insider's High School Premed Guidebook. His research team studies treatments to prevent sudden cardiac death, atrial fibrillation, and complications of cardiac device lead extraction. He has won numerous teaching awards for his work with medical students, residents, and fellows. He currently teaches ECG reading to medical students in the Stanford Medical School course INDE 205 Practice of Medicine. He also serves as Chief of Cardiac Electrophysiology at the Palo VA Medical Center and Head Cardiologist for University of California Athletics.
-
David Lee, MD
Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly Interests1. Novel treatments and devices for the treatment of valvular disease
2. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy
3. Novel approaches to coronary revascularization
4. Closure devices for atrial septal defects and patent foramen ovale
5. Novel treatments for hypertension -
Eleanor Levin
Clinical Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsCardiovascular Value Based Care, Cardio-Obstetrics, Dyslipidemia Treatment
-
Eldrin F. Lewis, MD, MPH
Simon H. Stertzer, MD, Professor
BioDr. Lewis is a board-certified, fellowship-trained specialist in cardiovascular medicine. He is the chief of the Division of Cardiovascular Medicine and a professor of cardiovascular medicine.
Dr. Lewis is an esteemed clinician-scientist who specializes in the care of patients with advanced heart failure. He is an internationally recognized expert on heart failure, heart transplant, and quality of life for heart failure patients. He cares deeply about his patients as well as his colleagues, the hospital, and the School of Medicine. Dr. Lewis is committed to diversity and inclusion, as well as expanding Stanford clinical research initiatives.
A fundamental principle of Dr. Lewis’ practice is his belief that “there is more to life than death,” that cardiovascular care should go beyond helping patients survive to also helping them enjoy the best possible quality of life.
Dr. Lewis has deep expertise in conducting clinical trials examining diagnostic and therapeutic approaches to heart failure. He has done innovative work to create systems for incorporating quality of life measures for cardiovascular patients into electronic health records. This research has received support from the National Heart, Lung and Blood Institute and the National Institutes of Health.
Much of his quality of life research has focused on patient-reported outcomes. Dr. Lewis emphasizes the importance of looking at how a disease, whether chronic or acute, impacts people’s ability to function and perform their activities of daily living. Strategies to improve patients’ well-being focus not only on their physical symptoms but also on depression, anxiety, exercise capacity, and ability to function in daily living.
Dr. Lewis’ commitment to expanding clinical research initiatives will give patients more opportunities to participate in the clinical trials and access the latest care strategies that can translate into better outcomes. The goal is early access to the most advanced technology, pharmacology, and device therapy that can change outcomes for the better. He also envisions forming closer partnerships with community cardiologists and capitalizing further on Stanford’s proximity to and unique relationships with the digital technology leaders of Silicon Valley to enhance the use of digital technology for monitoring patients, optimizing treatment, and tracking outcomes.
He has authored nearly 200 articles published in peer-reviewed journals including the New England Journal of Medicine, Journal of the American College of Cardiology, Circulation, JAMA Cardiology, JAMA Internal Medicine, and many more. He is also on multiple editorial boards for cardiovascular journals and was an associate editor for Circulation–Heart Failure. In addition, he is an author of professional society clinical practice guidelines and scientific statements from both the American Heart Association (AHA) and the Food and Drug Administration.
Dr. Lewis’ honors for clinical care, scholarship, and research include the Joel Gordon Miller Award for community service and leadership from the University of Pennsylvania School of Medicine. He also was one of the first recipients of the Minority Faculty Development Award, which recognizes the research potential of young physicians. Dr. Lewis has received a grant from the Robert Wood Johnson Foundation to study the role of quality of life assessment in clinical decision making in patients with heart failure.
He is a fellow of the American College of Cardiology and the National American Heart Association (AHA) Research Committee. In addition, Dr. Lewis was as a member of the AHA Founders Affiliate Board of Directors, chair of the Council on Clinical Cardiology, and research chair of the Association of Black Cardiologists. He also serves on scientific committees to review grants for the AHA and on the FDA Task Force for the Standardization of Definitions for Endpoint Events in Cardiovascular Trials. -
Daniel Yuhang Li
Instructor, Medicine - Cardiovascular Medicine
BioI am a physician scientist in the Division of Cardiology at Stanford. My clinical interest is at the intersection of inflammation, autoimmunity and cardiovascular disease in a field called 'Cardio-Rheumatology'. Patients with rheumatologic diseases typically have an elevated cardiovascular disease risk profile along with an insidious onset. Moreover, with the ever-expanding biologic drug formulary for patients, it is important for us to characterize the cardiovascular effects of these medications. In my research, I believe that understanding how inflammatory and autoimmune mechanisms modify coronary artery disease can help us develop a novel perspective towards treating atherosclerosis beyond lipid lowering. My research goal is to advance novel therapeutics for atherosclerosis by leveraging my expertise in genetics, computational biology, and experience with diverse model organism perturbation models. My strategy employs a ‘systems’ approach, starting with human population variations at the genetic level and integrating findings across RNA, protein, and model organism studies. This comprehensive synthesis aims to grasp the overarching biological narrative, thereby facilitating the development of translational therapies that transform concepts from bench to bedside.
-
Ronglih Liao
Douglass M. and Nola Leishman Professor of Cardiovascular Disease
BioDr. Liao is a Professor of Medicine and co-Director of Stanford Cardiac Amyloid Center. The major goal of her research program focuses on understanding the mechanisms that underlie the pathophysiology of heart failure and developing novel treatments to combat this process. Her laboratory has played an international leading role in the study of amyloid light chain (AL) cardiomyopathy, a rare and fatal form of cardiovascular disease. We have described the underlying pathophysiologic basis for amyloid cardiomyopathy and found that the circulating amyloidogenic light chain proteins that characterize this disease directly result in a specific cardiotoxic response. Consequently, our research work has redefined AL cardiomyopathy and has raised new treatment approaches. More recently, her research efforts have expanded to include transthyretin (ATTR) cardiac amyloidosis.
In line with her goal of revealing novel therapeutic strategies for patients with cardiovascular disease, our efforts have also focused on characterizing and harnessing endogenous cardiac regenerative mechanisms. Her laboratory initially demonstrated the therapeutic potential of exogenous primitive muscle cells delivered to the injured heart. This work was among the earliest milestones in the field and served as the basis for an international trial of cell-based therapy. Subsequently, Liao lab identified and characterized a population of cardiac progenitor cells and its relationship and dynamic activity following cardiac injury in the adult heart. Her laboratory aims to reveal the molecular mechanisms regulating the endogenous regenerative capacity of the heart and to harness such repair mechanisms for the treatment of cardiovascular disease. Dr. Liao has lectured extensively on both amyloid cardiomyopathy and stem cell biology, and have maintained a history of independent NIH funding in these areas for more than two decades.
Over the course of her academic career, she has taken the greatest pride in mentoring the next generation of scientists. Dr. Liao has had the privilege to supervise several dozen students, postdoctoral fellows, and junior faculty, many of whom have gone on to independent academic careers at the highest institutions. Her contribution to the advancement of scientific knowledge also includes lecturing at various university and academic institutions as well as at scores of conferences and symposia locally, nationally, and internationally. -
George Lui
Clinical Professor, Medicine - Cardiovascular Medicine
Clinical Professor, Pediatrics - CardiologyCurrent Research and Scholarly InterestsAdult Congenital Heart Disease
-
Kenneth Mahaffey
Professor of Medicine (Cardiovascular Medicine)
BioClinical Focus: Cardiovascular Medicine: Atrial Fibrillation; Chronic CAD; ACS;
Research Focus:
My primary research interest is the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. My research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies. I am also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events by Clinical Event Committees (CEC), and the efficient operational conduct of large multinational clinical trials.
Administrative Focus: Associate Dean, Clinical Research School of Medicine; Vice Chair of Clinical Research Department of Medicine; Director Stanford Center for Clinical Research; Member of the Stanford IRB
Professional Training:
1985 Stanford University, BS Chemistry
1989 University of Washington, MD
1993 University of Arizona, Internship/Residency/Chief Residency
1996 Duke University, Fellowship in Cardiology
1996 Duke University, Faculty in Cardiology
2013 Stanford University, Faculty Cardiovascular Medicine -
Anurag Mairal
Adjunct Professor, Medicine - Cardiovascular Medicine
Adjunct Professor, Medicine - Cardiovascular MedicineBioDr. Anurag Mairal is an Adjunct Professor of Medicine and the Director, Global Outreach Programs at Stanford Mussallem Center for Biodesign, Stanford University. He is also a Faculty Fellow and Lead for Technology Innovation and Impact at Center for Innovation in Global Health. In these roles, he leads initiatives focused on applying the biodesign process to resource-constrained settings globally. Further, he facilitates opportunities for students, faculty and fellows at Stanford to work on global healthcare needs. He is founding co-Director for MED 232, Global Health: Scaling Health Technology Innovations in Low Resource Settings, and was part of the founding faculty team for BIOE 371, Global Biodesign: Medical Technology in an International Context, graduate-level courses offered to engineering, business, and medical students at Stanford University. Earlier, he served as Associate Director for the Stanford-India Biodesign and Singapore-Stanford Biodesign programs. He serves as the Founding Chair of BME IDEA APAC, a community of medtech innovation programs in Asia Pacific, partnering closely with the industry and academia in the region. He is also an Honorary Professor at University of Cape Town, South Africa. Concurrently, he is a co-founder and Executive Vice President of Orbees Medical, a SF Bay Area-based strategy consulting firm serving global healthcare industry, with a focus on medtech, pharmaceutical, and digital health industry.
Dr. Mairal has an extensive background in medical technology development and commercialization, collaborating with partners in the U.S., India, China, and other emerging markets to advance product development, manufacturing, and distribution. Recently, he took a sabbatical for two years to take a senior leadership role at PATH, a major global health nonprofit based in Seattle. In this role, he oversaw research and development, commercialization, and implementation of technologies in PATH’s medical devices, diagnostics, and digital health divisions. Previously, he held several positions at Johnson & Johnson, including Business Development Director and Product Director for structural heart, cardiology, and peripheral vascular products at Cordis. Before joining J&J, he was a Group Leader and a Process Development Manager at Membrane Technology and Research (MTR). At MTR, he was responsible for business development, strategic alliances, and product development in the bioseparations area. An active mentor to entrepreneurs and industry professionals, he serves as the chair of PATH’s Bay Area Leadership Council; co-chair of the global advisory board at EPPIC Global Network; chair of Faculty Alumni Network and member of the Board Executive Committee at IIT Bombay Heritage Foundation; and President of Sewa International - Bay Area.
Dr. Mairal earned a PhD in chemical engineering from the University of Colorado at Boulder and an MBA from the Haas School of Business at the University of California at Berkeley. He also holds an MS in chemical engineering from the Indian Institution of Technology in Mumbai and a BS in chemical engineering from National Institute of Technology, Raipur. Dr. Mairal was a post-doctoral fellow at the University of Twente, Netherlands and at University of Michigan, Ann Arbor. At BerkeleyHaas, he was a founding co-Chairman of the South Asia Business Conference and Chair of the Biotech Panel for the Asia Business Conference. His work has been published in more than 30 publications, and he has seven issued patents. -
Joshua Makower
Yock Family Professor and Professor of Bioengineering
Current Research and Scholarly InterestsDr. Josh Makower is the Boston Scientific Applied Bioengineering Professor of Medicine and of Bioengineering at the Stanford University Schools of Medicine and Engineering and the Director of the Stanford Byers Center for Biodesign, the program he co-founded with Dr. Paul Yock twenty years ago. Josh helped create the fundamental structure of the Center’s core curriculum and is the chief architect of what is now called “The Biodesign Process.” Over the past 20 years since Josh and Paul founded Biodesign, this curriculum and the associated textbook has been used at Stanford and across the world to train hundreds of thousands of students, faculty and industry leaders on the Biodesign process towards the advancement of medical innovation for the improvement of patient care. Josh has practiced these same techniques directly as the Founder & Executive Chairman of ExploraMed, a medical device incubator, creating 9 companies since 1995. Transactions from the ExploraMed portfolio include NeoTract, acquired by Teleflex, Acclarent, acquired by J&J, EndoMatrix, acquired by C.R. Bard & TransVascular, acquired by Medtronic. Other ExploraMed/NEA ventures include Moximed, NC8 and Willow. Josh is also a Special Partner at NEA where he supports the healthcare team and medtech/healthtech investing practice. Josh serves on the boards of Allay Therapeutics, Revelle Aesthetics, Setpoint Medical, DOTS Technologies, Eargo, ExploraMed, Intrinsic Therapeutics, Moximed, Willow and Coravin. Josh holds over 300 patents and patent applications. He received an MBA from Columbia University, an MD from the NYU School of Medicine, a bachelor’s degree in Mechanical Engineering from MIT. Josh is a Member of the National Academy of Engineering and the College of Fellows of The American Institute for Medical and Biological Engineering and was awarded the Coulter Award for Healthcare Innovation by the Biomedical Engineering Society in 2018.
-
Neha Maheshwari Mantri
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Neha Mantri serves as the Director of the Structural Imaging Program and Director of the Women’s Cardiology Clinic at Palo Alto VA Health Care System (PAVA HCS). Given her expertise in advanced imaging, she serves as a reader in the Echocardiography Lab at Stanford Hospital. She also leads several echocardiography quality improvement projects, weekly multi-modality imaging educational seminars, and fellow workshops across the PAVA HCS and Stanford echo labs.
-
Michael V. McConnell, MD, MSEE
Clinical Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsMy imaging research has involved clinical and molecular Imaging of cardiovascular disease, with a focus on coronary and vascular diseases, including atherosclerosis, aortic aneurysms, and vascular inflammation.
My prevention research has involved innovative technologies to reduce coronary and vascular disease, including early disease detection plus leveraging mobile health and AI to enhance heart heart in patients and populations. -
Mark Mercola
Professor of Medicine (Cardiovascular) and, by courtesy, of Chemical and Systems Biology
BioDr. Mercola is Professor of Medicine and Professor in the Stanford Cardiovascular Institute. He completed postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School, was on the faculty in the Department of Cell Biology at Harvard Medical School for 12 years, and later at the Sanford-Burnham-Prebys Institute and Department of Bioengineering at the University of California, San Diego before relocating to Stanford in 2015.
Prof. Mercola is known for identifying many of the factors that are responsible for inducing and forming the heart, including the discovery that Wnt inhibition is a critical step in cardiogenesis that provided the conceptual basis and reagents for the large-scale production of cardiovascular tissues from pluripotent stem cells. He has collaborated with medicinal chemists, optical engineers and software developers to pioneer the use of patient iPSC-cardiomyocytes for disease modeling, safety pharmacology and drug development. His academic research is focused on developing and using quantitative high throughput assays of patient-specific cardiomyocyte function to discover druggable targets for preserving contractile function in heart failure and promoting regeneration following ischemic injury. He co-established drug screening and assay development at the Conrad Prebys Drug Discovery Center (San Diego), which operated as one of 4 large screening centers of the US National Institutes of Health (NIH) Molecular Libraries screening initiative and continues as one of the largest academic drug screening centers.
Prof. Mercola received an NIH MERIT award for his work on heart formation. He holds numerous patents, including describing the invention of the first engineered dominant negative protein and small molecules for stem cell and cancer applications. He serves on multiple editorial and advisory boards, including Vala Sciences, Regencor, The Ted Rogers Centre for Heart Research and the Human Biomolecular Research Institute. His laboratory is funded by the National Institutes of Health (NIH), California Institute for Regenerative Medicine, Phospholamban Foundation and Fondation Leducq. -
Sanjiv Narayan
Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly InterestsDr. Narayan directs the Computational Arrhythmia Research Laboratory, whose goal is to define the mechanisms underlying complex human heart rhythm disorders, to develop bioengineering-focused solutions to improve therapy that will be tested in clinical trials. The laboratory has been funded continuously since 2001 by the National Institutes of Health, AHA and ACC, and interlinks a disease-focused group of clinicians, computational physicists, bioengineers and trialists.
-
Koen Nieman
Professor of Medicine (Cardiovascular Medicine) and of Radiology (CV Imaging)
Current Research and Scholarly InterestsDr Nieman investigates advanced cardiac imaging techniques. Current projects focus on the development of functional CT application for hemodynamic interpretation of coronary artery disease, and the clinical validation of cardiac CT in the management of patients with ischemic heart disease.
-
Joyce Njoroge, MD
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Njoroge is a board-certified physician and fellowship-trained cardiologist with the Advanced Heart Failure Program at Stanford Health Care. She is also a clinical assistant professor of medicine in the Division of Cardiovascular Medicine.
Dr. Njoroge has extensive clinical experience diagnosing and treating cardiovascular complications that develop during pregnancy or postpartum. She currently provides care at the Stanford Health Care Heart and Vascular Clinic with a particular focus on patients with a history of pregnancy-associated heart failure and cardiomyopathy.
Dr. Njoroge’s research efforts involve identifying inherited genetic changes and biological markers that could help improve screening and care for pregnant women in higher risk populations. This includes determining the causes of disproportionately high incidences of heart-related complications and deaths experienced by Black women during and after pregnancy. Dr. Njoroge is also currently recruiting patients for a large-scale, multicenter clinical trial evaluating a drug to treat cardiovascular complications during pregnancy.
Dr. Njoroge has published her work in numerous prestigious peer-reviewed journals, including Circulation Research and the Journal of Cardiac Failure. She also co-authored a chapter on cardiovascular disease in pregnancy in the most recent edition of the book Current Diagnosis and Treatment: Cardiology.
Dr. Njoroge is a member of the Association of Black Cardiologists, the American College of Cardiology, the American Heart Association, and the Heart Failure Society of America. -
Latha Palaniappan, MD, MS
Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsDr. Palaniappan has published over 200 peer reviewed manuscripts, abstracts, and book chapters over the last 20 years in the areas of chronic disease prevention and treatment in diverse populations. She has expertise in epidemiological research using big data, use of electronic health records for research, and clinical trials.
-
Victoria Parikh, MD
Associate Professor of Medicine (Cardiovascular Medicine)
BioDr. Parikh is a clinician scientist who cares for patients with and studies inherited (genetic) cardiovascular disease. She is the director of the Stanford Center for Inherited Cardiovascular Disease (SCICD) which is one of the largest of its kind in the country. SCICD integrates clinical and basic science with the expert care of patients with genetic cardiovascular conditions (e.g., cardiomyopathies, arrhythmias and vascular diseases). It provides cutting edge care for thousands of patients and families across the lifespan and integrates medical, surgical and genetics care. Our team includes physicians, nurses, advanced practice providers, genetic counselors, exercise physiologists and scientists.
Dr. Parikh's own clinical practice and laboratory are focused on the genetics of cardiomyopathies and their associated arrhythmogenic substrates. She completed clinical cardiology fellowship at Stanford School of Medicine and her medical residency at the University of California, San Francisco. Funded by multiple research grants from the NIH, her lab seeks to identify novel mechanisms and therapeutic technologies for genetic cardiomyopathy as well as better understand the natural histories of patients affected by these diseases. -
Marco Perez
Associate Professor of Medicine (Cardiovascular Medicine)
BioDr. Marco Perez's research goal is to better understand the fundamental causes of cardiovascular disease through the study of genetics and epidemiology. His group studies the genetic variations and environmental exposures that are associated with conditions such as atrial fibrillation and heart failure. He has led the studies of atrial fibrillation in Women's Health Initiative, one of the largest nation-wide population-based cohorts. He is currently conducting a large study monitoring for silent or asymptomatic atrial fibrillation in women from the WHI randomized to exercise intervention, and was co-PI of the Apple Heart Study, a clinical trial that validated the ability of a smartwatch to detect atrial fibrillation. He is now PI of the Clinical Coordinating Center at Stanford for the REACT-AF which is a clinical trial to evaluate efficacy and safety of a "pill-in-the pocket" approach to anticoagulation for AF using a smartwatch. He is interested in understanding the paradox that atrial fibrillation is less common in African Americans and Hispanics, despite a greater burden of risk factors such as hypertension. As director of the Stanford Inherited Arrhythmia Clinic, he evaluates families with rare inherited arrhythmias associated with sudden death such as Long QT and Brugada Syndromes and explores their links with novel genes. He also studies the genetic causes of very early onset atrial fibrillation. He also studies how best to use the electrocardiogram and imaging modalities using Machine Learning techniques to identify patients at risk for cardiovascular disease. Dr. Perez receives funding from the NIH/NHLBI, Apple Inc., Janssen and the Colson Foundation.
-
Alexander C. Perino
Clinical Associate Professor, Medicine - Cardiovascular Medicine
BioAlexander C. Perino, MD is a cardiac electrophysiologist at Stanford Health Care whose primary focus is providing procedural care for patients with heart rhythm disorders. He performs a wide range of ablation and cardiac device implantation procedures, utilizing cutting-edge techniques and technologies to deliver high-quality, patient-centered care.
Dr. Perino serves as the Director of the Electrophysiology Laboratory at Stanford Health Care, where he leads efforts to enhance procedural quality, safety, and patient outcomes across the electrophysiology program. He is also the principal investigator for numerous clinical trials, working to ensure that patients have the opportunity to participate in research and contribute to scientific advancement—without compromising the quality of their care.
In addition, Dr. Perino is the Medical Informatics Director for the Division of Cardiovascular Medicine at Stanford Health Care. In this role, he oversees initiatives aimed at improving the quality and safety of cardiovascular care, while optimizing the electronic health record to better support patients and clinicians alike. -
Jena Pizula, MD
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Pizula is a quadruple board-certified, fellowship-trained cardiologist with Stanford Health Care Cardiovascular Health. She is also a clinical assistant professor in the Department of Medicine, Division of Cardiovascular Medicine at Stanford University School of Medicine. She completed a fellowship in cardiovascular medicine at the University of Southern California (USC) Keck School of Medicine.
Dr. Pizula specializes in cardio-obstetrics. She works with women before, during, and after pregnancy to determine their risk of heart-related pregnancy complications and improve their cardiovascular health. She has experience managing complex cardiovascular conditions, including congenital heart disease, arrhythmias, coronary artery disease, valvular disease, and cardiomyopathy. Dr. Pizula develops a customized care plan for each patient she treats. As a leader in cardio-obstetrics, she’s at the forefront of the latest advances in women’s cardiovascular care.
Her research interests include the intersection of cardiovascular disease and pregnancy. She focuses on how pre-existing conditions like congenital heart disease, cardiomyopathy, or hypertension affect pregnancy. She has also explored how physiological changes during pregnancy affect existing heart disease and long-term cardiovascular risk. She uses her unique dual background in internal medicine and pediatrics to study how adult manifestations of cardiovascular disease impact pregnancy outcomes.
Dr. Pizula is active in teaching medical students, internal medicine and obstetrical residents, and cardiology fellows. She teaches them strategies to improve how they assess and manage risk and deliver postpartum care to people with high-risk cardiac pregnancies. Dr. Pizula is the director of the Finishing School for Future Cardiologists for the California chapter of the American College of Cardiology, which offers leadership development to cardiology fellows.
Dr. Pizula’s research has been published in the Journal of the American Heart Association, Journal of the American College of Cardiology, The Journal of Heart and Lung Transplantation, Journal of General Internal Medicine, and Pediatrics. She has authored three book chapters on cardio-obstetrics and global emergency medicine.
Dr. Pizula has presented her research at conferences in the United States and internationally. As an expert in cardiovascular disease and pregnancy, she is frequently invited to speak to cardiologists, obstetricians, and anesthesiologists at the International Congress on Cardiac Problems in Pregnancy. She currently serves as a reviewer for the European Journal of Heart Failure and Heart Failure Reviews.
Dr. Pizula is a member of the American College of Cardiology, Stanford Medicine Cardiovascular Institute, and Stanford Medicine Maternal & Child Health Research Institute. -
Richard Popp
Professor of Medicine (Cardiovascular Medicine), Emeritus
Current Research and Scholarly InterestsAcademic-Industrial relations; Ethics of invention.
-
Krishna Pundi
Clinical Instructor, Medicine - Cardiovascular Medicine
BioKrishna Pundi, MD is a cardiac electrophysiologist and health services and outcomes researcher with a clinical interest in the management of ventricular arrhythmias and atrial fibrillation.
Dr. Pundi leads a multidisciplinary research program to study (1) clinical and arrhythmia-specific factors that predict cardiovascular risk for ventricular arrhythmias, (2) the interplay of frailty and obesity with atrial fibrillation outcomes, and (3) the role of digital health and wearables in arrhythmia care. He has led grant-funded research through the NIH, FDA, and ACC and collaborations with large device and quality databases including AHA’s Get With the Guidelines. He has a special interest in innovation and regulatory science, having organized national Think Tanks of patients, investigators, and FDA to define the scientific and clinical use of wearable monitors. Dr. Pundi holds leadership roles through the American College of Cardiology, Heart Rhythm Society, Cardiovascular Sciences Research Consortium, and HRX - an innovation-focused meeting of clinicians, researcher, and industry. -
Thomas Quertermous, MD
William G. Irwin Professor of Cardiovascular Medicine
Current Research and Scholarly InterestsUnderstanding genetic basis of cardiovascular function and disease.
-
Sameer Raina, MD, MBBS, MBA, FACC
Clinical Associate Professor, Medicine - Cardiovascular Medicine
BioDr. Raina is a board-certified cardiologist in the General Cardiology clinic at Stanford Health Care and a member of the Stanford Cardiovascular Institute. He is also a clinical associate professor in the Division of Cardiovascular Medicine.
His clinical interests include preventive cardiology, cardiac rehabilitation, and sports cardiology. In his recent positions at West Virginia University, he established the cardiology telemedicine program during and after the COVID pandemic. He applied his passion for cardiac rehab by creating individualized treatment plans for college athletes recovering from COVID. Dr. Raina is also passionate about building relationships with community doctors. He believes continuous communication is an essential part of excellent patient care.
Dr. Raina’s current research focuses on preventive cardiology, cardiac imaging, and outcomes research. He studies the outcomes of different cardiac interventions in specific patient populations. His research helps identify appropriate treatments for patients who have other conditions in addition to heart disease.
Dr. Raina eagerly anticipates joining the faculty of the Stanford South Asian Translational Heart Initiative (SSATHI). He is excited for the opportunity to address the high risk of cardiovascular diseases among South Asians. He looks forward to applying his clinical and research experience to support SSATHI’s mission to provide advanced care to ethnic populations disproportionately affected by these diseases.
Dr. Raina is a peer reviewer for several prestigious publications, including Neuropsychiatric Disease and Treatment and the International Journal of Chronic Obstructive Pulmonary Disease. He has also been an invited guest speaker at national and international meetings, including those for the International Congress of Cardiology and the World Congress of Cardiothoracic-Renal Diseases.
Dr. Raina is a fellow of the American College of Cardiology (FACC) and a member of the American College of Cardiology. -
Risheen Reejhsinghani
Clinical Associate Professor, Medicine - Cardiovascular Medicine
BioRisheen Reejhsinghani obtained her medical degree in Mumbai, India, followed by an internal medicine residency at St. Elizabeth's Medical Center in Boston, MA and cardiology fellowship at Baystate Medical Center/Tufts University School of Medicine, where she served as one of the chief fellows. She subsequently completed an advanced echocardiography fellowship at the University of California, San Francisco, and is board certified in echocardiography, general cardiology, and nuclear cardiology.
Dr. Reejhsinghani practices as a general cardiologist in the Division of Cardiovascular Medicine at Stanford University School of Medicine, where she also serves as the associate director for the hospital-based consultative cardiology service. As a clinical cardiologist, she believes strongly in the tenets of evidence-based practice, diagnostic cognizance, and patient education. She also has a specific interest in the burgeoning field of Cardio-Rheumatology, focused on cardiac diseases among patients with rheumatologic conditions such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, and ankylosing spondylitis, among others. Her clinical research in this area has focused on the evaluation of structural cardiac disease and diastolic dysfunction in ankylosing spondylitis patients, primarily using echocardiography.
Dr. Reejhsinghani has an academic focus in medical education, and believes that instilling a love for bedside medicine and the physical exam is the soundest way to empower future generations of learners. To this end, she received additional training in clinical teaching and simulation at the University of California, San Francisco, and has worked extensively on curriculum and course design. She currently serves as the associate program director of the cardiovascular medicine fellowship at Stanford, and is an associate course director for the Year 1 Practice of Medicine Course at the Stanford University medical school. Dr. Reejhsinghani also enjoys writing, particularly about medical education and has written articles for international newspapers, among other publications. -
Stanley G. Rockson, MD
Allan and Tina Neill Professor of Lymphatic Research and Medicine
Current Research and Scholarly InterestsMy clinical research includes studies on risk factor modification in atherosclerosis and coronary artery disease; clinical trials involving medical therapies for peripheral arterial insufficiency; coronary angiogenesis; therapy of lymphedema; atherand photodynamic therapy in atherosclerosis.
-
Fatima Rodriguez
Associate Professor of Medicine (Cardiovascular Medicine)
BioFatima Rodriguez, MD, MPH serves as the Vice Chair of Clinical Research (Department of Medicine), Section Chief of Preventive Cardiology, and Associate Director of the Center for Digital Health at Stanford University. She received her medical degree from Harvard Medical School and a Master of Public Health from the Harvard T.H. Chan School of Public Health. Dr. Rodriguez completed her internal medicine residency at Brigham and Women’s Hospital and fellowship in cardiovascular medicine at Stanford.
Dr. Rodriguez specializes in the prevention and management of cardiovascular disease, with clinical expertise in coronary artery disease and inherited lipid disorders. Her research focuses on cardiovascular disease prevention and health promotion, leveraging digital tools to improve guideline-based care, and using AI-enabled approaches for early detection of atherosclerosis. -
Albert "A.J." Rogers, MD, MBA, FAHA
Instructor, Medicine - Cardiovascular Medicine
BioDr. Rogers is a board-certified, fellowship-trained cardiologist with the Cardiac Arrhythmia Service at Stanford Health Care. He is also an instructor of medicine in the Division of Cardiovascular Medicine, Department of Medicine at Stanford University School of Medicine.
As a clinical cardiac electrophysiologist, Dr. Rogers’ training includes evaluating issues involving electrical activity in the heart and how these can lead to an abnormal heart rhythm (arrhythmia). His expertise includes mapping regions in the heart associated with arrhythmias and then applying a minimally invasive therapy (ablation) that targets the responsible areas causing the problem. He also performs procedures to implant cardiac devices, such as pacemakers and defibrillators, designed to synchronize heart contractions and reset irregular heartbeats.
Dr. Rogers specializes in the diagnosis and treatment of atrial fibrillation, ventricular tachycardia, and other arrhythmias. In collaboration with Stanford Medicine cardiovascular surgeons, he performs hybrid surgical-catheter ablation procedures as a more permanent treatment for persistent forms of atrial fibrillation and for inappropriate sinus tachycardia. During this procedure, ablation therapy is applied to areas both inside and outside of the heart responsible for the arrhythmia.
As a physician-researcher, Dr. Rogers’ translational research applies biomedical engineering and machine learning approaches to explore the mechanisms underlying cardiac arrhythmia. These efforts include research funded by the National Institutes of Health and the American Heart Association to investigate novel methods for diagnosing and treating heart rhythm disorders. Dr. Rogers has over 10 years of experience with medical technology innovation and development.
Dr. Rogers serves as associate editor of the Journal of Invasive Cardiovascular Electrophysiology. He is also a peer reviewer for multiple prestigious journals, including Heart Rhythm, The Lancet: Digital Health, the Journal of the American College of Cardiology: Clinical Electrophysiology, and Frontiers in Physiology. He has been an invited guest speaker at national and international meetings, including those for the American Heart Association and the European Cardiac Arrythmia Society. -
Karim Sallam, MD
Assistant Professor of Medicine (Cardiovascular Medicine)
BioKarim Sallam, MD, is trained in Cardiovascular Medicine and Advanced Heart Failure.
-
Ryan Sandoval, M.D.
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Sandoval is a board-certified cardiologist and a clinical assistant professor in the Division of Cardiovascular Medicine at Stanford University School of Medicine. He completed his residency at the University of Texas at Austin, where he continued on as chief resident before going on to complete his fellowship in cardiovascular disease at the Medical University of South Carolina. Prior to his residency, he completed a research fellowship at Massachusetts General Hospital (MGH).
His clinical interests include preventive cardiology and management of heart failure. He is particularly focused on treating patients with the complex clinical syndrome of heart failure with preserved ejection fraction (HFpEF).
His interest in preventive cardiology grew through his participation in clinics for the uninsured and underinsured during his training. These experiences fostered his passion for understanding and addressing health care disparities. He is deeply committed to providing exceptional patient care with a personalized approach to treatment and improving the lives of his patients.
He is a member of the American College of Cardiology. -
Ingela Schnittger, MD
Professor of Medicine (Cardiovascular)
Current Research and Scholarly InterestsMy main research continues to be in the field of echocardiography. Several areas of research are currently being pursued.
-
John S. Schroeder, MD
Professor (Clinical) of Medicine (Cardiovascular), Emeritus
Current Research and Scholarly Interests1. Clinical Pharmocology of Cardiovascular Drugs
(a) Calcium Channel Blockers
(b) Agents for Heart Failure
(c) Anti-atherosclerotic Effects of Cardiovascular Drugs, e.g. Calcium Channel Blockers
2. Cardiac Transplantation/Congestive Heart Failure
3. Coronary Artery Spasm -
Rahul P Sharma, MBBS, FRACP
Clinical Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsTranscatheter valve therapies, CT valve imaging, AI and device innovation
-
Joshua M. Spin
Clinical Associate Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsDr. Spin began his research career studying the structural biology of low density lipoprotein, and has had intensive training in molecular biology techniques, particularly high-throughput genetic expression profiling. He is especially interested in vascular smooth muscle cells, and the role of smooth muscle differentiation and phenotypic switching in development, and in vascular disease. His latest work has focused on the biology of aortic aneurysms.
-
Juwono L. Sutedjo, MD, MBA
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Sutedjo is a board-certified, fellowship-trained cardiologist. She is a faculty in the Department of Medicine, Division of Cardiovascular Medicine at Stanford University School of Medicine.
Dr. Sutedjo holds seven board certifications. She specializes in complex cardiovascular conditions, emphasizing multimodality cardiovascular imaging and disease prevention. She integrates leading-edge diagnostics with evidence-based strategies to provide comprehensive, patient-centered care. She has led multidisciplinary clinics, telehealth programs, and ambulatory operations to enhance accessibility and efficiency.
Dr. Sutedjo has a visionary approach to the future of cardiovascular medicine, particularly in the context of the rapidly evolving digital era. With a clear understanding of the need for innovative business models in healthcare, she pursued an MBA from the Wharton School of the University of Pennsylvania to complement her medical expertise. As a physician executive and clinical researcher, she has deep expertise in clinical operations, health care delivery, and finance. Her diverse background spans private practice, integrated healthcare systems, and managed care settings, providing her with a comprehensive perspective on the healthcare landscape. Driven by a commitment to enhancing patient outcomes, Dr. Sutedjo is deeply invested in leveraging digital health innovations and artificial intelligence to advance the field of cardiovascular care.
Dr. Sutedjo’s research explores AI, machine learning, and digital health applications in cardiovascular risk prediction, diagnosis, and treatment. She aims to improve efficiency, reduce disparities, and enhance precision in clinical decision-making.
Dr. Sutedjo has published her work in Circulation, The American Journal of Medicine, and 21st Century Cardiology. She has also presented at the American Heart Association Scientific Sessions and other national and international conferences, engaging with industry leaders and private sector stakeholders on the role of AI in health care. She has co-founded several health technology startups and served as a consultant for leading technology companies and private sector organizations. Additionally, she played a key role in the IPO of a tech startup on the Toronto Stock Exchange.
